

# CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

NCT06839976

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Children's Hospital of Philadelphia
<b>Enrollment</b>	24 participants

## Key Eligibility Criteria

---

### Inclusion (19)

- Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window.
- Patient age must be 12-29 years, inclusive, at time of enrollment.
- Meeting ACR/EULAR Classification Criteria for SLE
- ANA positive  $\geq$  1:80 and/or double-stranded DNA (dsDNA) positive
- Active (refractory) disease, defined as follows:  
... and 14 more (see full listing online)

### Exclusion (17)

- Active, untreated infections
- HIV infection
- Active Hepatitis B
- a. Patients must have a negative hepatitis B surface antigen to be enrolled on this study.
- Active Hepatitis C  
... and 12 more (see full listing online)

## Locations (1 total)

---

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

---

<https://clinicaltrials.gov/study/NCT06839976>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).